iView Therapeutics

IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced its participation in the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. IVIEW will present one oral presentation and four posters highlighting advancments in dry eye, gene therapy, ocular…

IVIEW Therapeutics Inc. (“IVIEW”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative ophthalmic therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 3 clinical trial for IVIEW-1701. IVIEW-1701 is an innovative drug…

IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds. The procedure was performed under the direction of…

IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. This important milestone marks the program’s entry into a new phase of global, pivotal clinical development and represents a major step…

IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO…

First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research…

IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO  The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic…

IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations…